TY - JOUR
T1 - Superagonist, Full Agonist, Partial Agonist, and Antagonist Actions of Arylguanidines at 5-Hydroxytryptamine-3 (5-HT3) Subunit A Receptors
AU - Alix, Katie
AU - Khatri, Shailesh
AU - Mosier, Philip D.
AU - Casterlow, Samantha
AU - Yan, Dong
AU - Nyce, Heather L.
AU - White, Michael M.
AU - Schulte, Marvin K.
AU - Dukat, Małgorzata
N1 - Publisher Copyright:
© 2016 American Chemical Society.
PY - 2016/11/16
Y1 - 2016/11/16
N2 - Introduction of minor variations to the substitution pattern of arylguanidine 5-hydroxytryptamine-3 (5-HT3) receptor ligands resulted in a broad spectrum of functionally-active ligands from antagonist to superagonist. For example, (i) introduction of an additional Cl-substituent(s) to our lead full agonist N-(3-chlorophenyl)guanidine (mCPG, 2; efficacy % = 106) yielded superagonists 7-9 (efficacy % = 186, 139, and 129, respectively), (ii) a positional isomer of 2, p-Cl analog 11, displayed partial agonist actions (efficacy % = 12), and (iii) replacing the halogen atom at the meta or para position with an electron donating OCH3 group or a stronger electron withdrawing (i.e., CF3) group resulted in antagonists 13-16. We posit based on combined mutagenesis, crystallographic, and computational analyses that for the 5-HT3 receptor, the arylguanidines that are better able to simultaneously engage the primary and complementary subunits, thus keeping them in close proximity, have greater agonist character while those that are deficient in this ability are antagonists.
AB - Introduction of minor variations to the substitution pattern of arylguanidine 5-hydroxytryptamine-3 (5-HT3) receptor ligands resulted in a broad spectrum of functionally-active ligands from antagonist to superagonist. For example, (i) introduction of an additional Cl-substituent(s) to our lead full agonist N-(3-chlorophenyl)guanidine (mCPG, 2; efficacy % = 106) yielded superagonists 7-9 (efficacy % = 186, 139, and 129, respectively), (ii) a positional isomer of 2, p-Cl analog 11, displayed partial agonist actions (efficacy % = 12), and (iii) replacing the halogen atom at the meta or para position with an electron donating OCH3 group or a stronger electron withdrawing (i.e., CF3) group resulted in antagonists 13-16. We posit based on combined mutagenesis, crystallographic, and computational analyses that for the 5-HT3 receptor, the arylguanidines that are better able to simultaneously engage the primary and complementary subunits, thus keeping them in close proximity, have greater agonist character while those that are deficient in this ability are antagonists.
KW - 3D-graphic models
KW - 5-HT receptors
KW - Arylguanidines
KW - binding affinities
KW - functional activities
KW - SAR
KW - site-directed mutagenesis
UR - http://www.scopus.com/inward/record.url?scp=84996554544&partnerID=8YFLogxK
U2 - 10.1021/acschemneuro.6b00196
DO - 10.1021/acschemneuro.6b00196
M3 - Article
C2 - 27533595
AN - SCOPUS:84996554544
SN - 1948-7193
VL - 7
SP - 1565
EP - 1574
JO - ACS Chemical Neuroscience
JF - ACS Chemical Neuroscience
IS - 11
ER -